Opportunity Analysis of H1N1 (swine flu) Vaccination Market published by Markets and Markets in November, 2009. This report consists of 126 pages and the price starts from US $ 4650.
Abstract
REPORT DESCRIPTION
H1N1 Influenza A (2009) is the first pandemic influenza of 21st century
affecting more than more than four lac people in more than 180 countries
across the globe in 2009. The flu broke in Mexico in the month of March and
then affected U.S. and after that it spread across the globe. H1N1 (2009)
influenza have a mutation of pig, bird and humans which has made it more
dangerous and fatal compared to previous occurrence of H1N1 (1918).
The pandemic outbreak of the influenza opened the gates for the drugs such as
Tamiflu in the initial phase for the curing of the disease but the following
phase will see a shift from curing to prevention. Thus, arise the requirement
for the vaccine for the treatment of H1N1. H1N1 vaccine market is the forecast
for the upcoming vaccines for the prevention of the disease among the
unaffected population. The vaccines market is classified for the intramuscular
vaccines and intranasal vaccines. Intramuscular will cater 80-85% of market
revenues and the remaining will be tapped by the intranasal vaccines. The
initial lot of vaccines will be of egg based and cell based manufacturing. The
market forecast is from late 2009 as the first lot of doses are expected to be
rolled out in the first week of October 2009.
The first movers of the in the vaccines market are Glaxo Smith Kline (GSK),
Novartis, CSL, Medimmune, Baxter, Sinovec and Sanofi Pastuer. Medimmune is the
only producer of the intranasal vaccine whereas other companies are expected
to come out with intramuscular vaccines. The companies have got approvals for
their first lots from the governments of the various countries such as U.S.,
U.K., France, China, Denmark and Australia. The involvement of government
bodies, increased awareness about prevention and pandemic situation of the
influenza is driving the market for the vaccines.
Due to intensive ongoing research and technology introduction, the market
players are compelled to understand the market dynamics, innovations,
pricing, products, marketing and regulatory framework of the market.
The global H1N1 Influenza vaccine market is estimated to be of 676 million in
2009 with first lot of doses being commercialized on 30th September' 2009. The
market will see a high CAGR for the next two years i.e. the market is expected
to be at $7.03 billion in 2011 with a CAGR of 222.4% from 2009 to 2011.
However, the very high CAGR will settle down by 2012 to 30% for the period of
2009 to 2012. The reason for the sudden settle down of the growth is that it
is expected that most of the world population will be immunized by the end of
2011.
Market estimates and forecast
This report will enable strategic understanding and opportunities in the H1N1
2009 influenza vaccines market. The report covers the following market
segments.
Table of Contents
EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL H1N1 2009 INFLUENZA VACCINE MARKET, BY PRODUCTS
- GLOBAL H1N1 2009 INFLUENZA VACCINE MARKET, BY GEOGRAPHY
- COMPETITIVE SCENARIO
1. INTRODUCTION
- KEY TAKE-AWAYS
- REPORT DESCRIPTION
- SCOPE AND FORMAT
- STAKEHOLDERS
2. SUMMARY
3. MARKET OVERVIEW
- 1918 SPANISH INFLUENZA (H1N1) PANDEMIC
- 1957 - ASIAN FLU (H2N2)
- 1968 - HONGKONG FLU
- 2009 H1N1 INFLUENZA
4. MARKET DYNAMICS
- DRIVERS & RESTRAINTS
- COST OF H1N1 VACCINE
- VACCINE AWARENESS
- SIDE-EFFECTS OF VACCINE
- AVAILABILITY OF SUBSTITUTE TREATMENT
- MARKET FORCES ANALYSIS
- SUPPLY-SIDE DRIVERS
- DEMAND-SIDE DRIVERS
- RESTRAINTS & OPPORTUNITIES
- PRICING OF H1N1 VACCINE
- CONSUMER INSIGHTS
5. GLOBAL H1N1 2009 INFLUENZA VACCINE MARKET
- MARKET OVERVIEW
- PRIORITY GROUPS FOR THE H1N1 VACCINE
- DRIVERS & RESTRAINTS
- PUBLIC-PRIVATE PARTNERSHIPS FOR SUPPLY OF H1N1 VACCINE
- GOVERNMENT SUBSIDIES FOR VACCINE MANUFACTURE
- REVENUE-INCREASING SOURCE
- HIGH COSTS & LENGTHY MANUFACTURING PROCESS
- OPPORTUNITIES
- SHIFT FROM EGG-BASED TO CELL-BASED MANUFACTURING
- MARKET FOR ADJUVANTS
- OPPORTUNITY FOR EMERGING ECONOMIES
- MANUFACTURING PROCESS OF INFLUENZA VACCINES
- EGG-BASED MANUFACTURING
- CELL-BASED MANUFACTURING
- RECOMBINANT TECHNOLOGY
- INTRAMUSCULAR H1N1 VACCINE MARKET
- DRIVERS & RESTRAINTS
- Caters to large population segment
- Rates low on user-friendliness
- INTRANASAL H1N1 VACCINE
- DRIVERS & RESTRAINTS
- User-friendly administration
- Fewer side-effects & improved efficacy
- Insurance coverage
- Limited consumer segment
- COMPETITIVE ANALYSIS
- BENCHMARKING OF APPROVED VACCINE
- PIPELINE OVERVIEW OF H1N1 VACCINE
6. GEOGRAPHICAL ANALYSIS OF GLOBAL H1N1 VACCINE MARKET
- MOON MATRIX ANALYSIS OF GLOBAL 2009 H1N1 INFLUENZA VACCINE, BY GEOGRAPHY
- HEALTHCARE EXPENDITURE & GOVERNMENT CONTRACTS
- SPREAD OF H1N1 & AVAILABILITY OF H1N1 VACCINE
- NORTH AMERICAN H1N1 VACCINE MARKET
- EUROPE H1N1 VACCINE MARKET
- ASIA PACIFIC H1N1 VACCINE MARKET
- AUSTRALIA
- CHINA.
- JAPAN.
- INDIA
- REST OF WORLD (ROW) H1N1 VACCINE MARKET
7. STRATEGIC CONCLUSION
8. COMPANY PROFILES
- BAXTER INTERNATIONAL INC
- BUTANTAN INSTITUTE
- CANTACUZINO INSTITUTE OF SERA AND VACCINES
- CHANGCHUN INSTITUTE OF BIOLOGICAL PRODUCTS
- CRUCELL N.V.
- CSL
- DENKA SEIKEN CO LTD
- GREEN CROSS CORP
- GLAXOSMITHKLINE PLC
- HUALAN BIOLOGICAL ENGINEERING INC
- INOVIO BIOMEDICAL CORP
- KITASATO INSTITUTE
- MEDIMMUNE
- MERCK & CO
- NOVARTIS
- NOVAVAX
- OMNINVEST
- PANACEA BIOTEC
- SANOFI-PASTEUR
- SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS
- SINOVAC BIOTECH LTD
- SERUM INSTITUTE OF INDIA LTD
- SOLVAY
- ZHEJIANG TIANYUAN BIO-PHARMACEUTICAL CO, LTD
- APPENDIX
- WORLD H1N1 INFLUENZA CASES IN OCTOBER 2009
- COUNTRY WISE DEATH RATES BY H1N1 FLU TILL OCTOBER 2009
LIST OF TABLES
- SUMMARY TABLE GLOBAL MARKET FOR 2009 H1N1 INFLUENZA VACCINE BY PRODUCTS
2009 - 2011 ($MILLIONS)
- TABLE 1 WHO-DEFINED LEVELS OF INFLUENZA PANDEMIC
- TABLE 2 GLOBAL H1N1 2009 INFLUENZA VACCINE MARKET, BY PRODUCTS 2009 -
2011 ($MILLIONS)
- TABLE 3 GLOBAL H1N1 INFLUENZA VACCINE MARKET, BY GEOGRAPHY 2009 - 2011
($MILLIONS)
- TABLE 4 GLOBAL MARKET FOR INTRAMUSCULAR H1N1 VACCINES, BY GEOGRAPHY 2009
- 2011 ($MILLIONS)
- TABLE 5 GOVERNMENT INTIATIVES FOR H1N1 VACCINE
- TABLE 6 CONTRACTS FOR H1N1 VACCINE
- TABLE 7 MARKET DEVELOPMENT FOR H1N1 VACCINE
- TABLE 8 BENCHMARKING OF VACCINE
- TABLE 9 TECHNOLOGY & DELIVERY OF VACCINE
- TABLE 10 H1N1 VACCINE TRIALS
- TABLE 11 NORTH AMERICAN MARKET FOR H1N1 INFLUENZA VACCINE, 2009 - 2011
($MILLIONS)
- TABLE 12 ASIA PACIFIC MARKET FOR H1N1 VACCINE, 2009- 2011 ($MILLIONS)
LIST OF FIGURES
- FIGURE 1 PANDEMIC WAVE DIAGRAM - SPANISH INFLUENZA
- FIGURE 2 SPANISH FLU FATALITIES IN THE U.S. (1918-1919)
- FIGURE 3 PANDEMIC SCENARIO OF HONG KONG FLU
- FIGURE 4 PANDEMIC INFLUENZA CYCLE
- FIGURE 5 H1N1 2009 INFLUENZA VACCINE MARKET DYNAMICS
- FIGURE 6 TIER PRICING MODEL FOR H1N1 VACCINE
- FIGURE 7 CONSUMER PERSPECTIVE FOR H1N1 VACCINE MARKET
- FIGURE 8 PRODUCT LIFECYCLE IN H1N1 VACCINE MARKET
- FIGURE 9 RECOMMENDED PRIORITY GROUPS FOR 2009 H1N1 INFLUENZA VACCINE
- FIGURE 10 TIMELINE OF COMMERCIALIZATION OF H1N1 VACCINE
- FIGURE 11 CONTRACT SHARING OF COMPANIES (2009)
- FIGURE 12 GLOBAL SCENARIO OF INFLUENZA PANDEMIC
- FIGURE 13 GLOBAL H1N1 INFLUENZA VACCINE MARKET, BY GEOGRAPHY
- FIGURE 14 MOON MATRIX OF H1N1 VACCINE MARKET, BY GEOGRAPHY
